^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

Excerpt:
In a cohort of patients with HER2-overexpressing breast cancer treated with trastuzumab, higher pretreatment tumor levels of survivin RNA correlated with poor response to therapy.
DOI:
10.1158/0008-5472.CAN-12-2440